Synthetic retinoid fenretinide in breast cancer chemoprevention

Research output: Contribution to journalArticlepeer-review


Preclinical models suggest that refinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenrefinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenrefinide in breast cancer chemoprevention.

Original languageEnglish
Pages (from-to)423-432
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number4
Publication statusPublished - Apr 2007


  • Breast neoplasm
  • Chemoprevention
  • Clinical trial
  • Fenretinide
  • Retinoid

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology


Dive into the research topics of 'Synthetic retinoid fenretinide in breast cancer chemoprevention'. Together they form a unique fingerprint.

Cite this